Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19

Last updated: July 4, 2021
Sponsor: China Academy of Chinese Medical Sciences
Overall Status: Suspended

Phase

2/3

Condition

Covid-19

Treatment

N/A

Clinical Study ID

NCT04278963
YHQW-V3.0
  • Ages > 18
  • All Genders

Study Summary

In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia caused by CoVID-19, and the number of cases of infection with CoVID-19 identified in Wuhan increased markedly over the later part of January 2020, with cases identified in multiple other Provinces of China and internationally.

Given no specific antiviral therapy for CoVID-19 infection and the availability of Yinhu Qingwen Decoction as a potential antiviral Chinese medicine based on vivo antiviral studies in CoVID-19, this randomized,three-arm controlled, single-blind trial will evaluate the efficacy and safety of Yinhu Qingwen Decoction (Granula) in patients hospitalized with mild or common CoVID-19 respiratory disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age ≥18 years at time of signing Informed Consent Form.
  2. Laboratory (RT-PCR) confirmed infection with CoVID-19.
  3. Hospitalised with Fever(≥36.7℃ -axilla or oral temperature ≥ 38.0 ℃ or ≥38.6°Ctympanic or rectal) and cough;
  4. No difficulty swallowing oral medications.
  5. Must agree not to enroll in another study of an investigational agent prior tocompletion of Day 28 of study.

Exclusion

Exclusion Criteria:

  1. Allergies, known to be allergic to research drugs or drug excipients;
  2. Patient weight is less than 40 kg;
  3. Respiratory distress-RR≥30 / min on room air,or SPO2≤ 93%, or PaO2/FiO2 ≤300mmHg (1mmHg = 0.133kPa)
  4. Shock;
  5. The clinician judges that ICU monitoring treatment is needed;
  6. Patients who have participated in other clinical trials within 1 month;
  7. Known patients with impaired renal function (estimated creatinine clearance <60 mL /min (male: Cr (ml / min) = (140-age) × body weight (kg) / 72 × blood creatinineconcentration (mg / dl); female: Cr (ml / min) = (140-age) × weight (kg) / 85 × bloodcreatinine concentration (mg / dl));
  8. During the screening or within 24 hours before screening, patients were found to haveany of the following laboratory parameter abnormalities (based on local laboratoryreference range):-ALT or AST level> 5 times the upper limit of normal range (ULN)or-ALT or AST > 3 times ULN and total bilirubin levels> 2 times ULN;
  9. Being pregnant or breastfeeding, or having a positive pregnancy test at the time ofpre-dose inspection, or planning to become pregnant within 3 months of studytreatment.

Study Design

Total Participants: 300
Study Start date:
October 01, 2021
Estimated Completion Date:
May 31, 2023

Study Description

In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia caused by CoVID-19, and the number of cases of infection with CoVID-19 identified in Wuhan increased markedly over the later part of January 2020, with cases identified in multiple other Provinces of China and internationally.

The clinical spectrum of CoVID-19 infection appears to be wide,including asymptomatic infection, mild upper respiratory disease, severe viral pneumonia with respiratory failure, and even death.However,there is no specific antiviral therapy for CoVID-19 infection, which provides a window of opportunity for testing candidate antiviral therapies. Previous experiences with SARS and MERS-CoV, highlight the need of the early intervention with Chinese medicine, and so as for CoVID-19 infection. The treatment of Chinese medicine for CoVID-19 infection suggested its benefits to improve of clinical outcomes, reduce the risk of disease progression, accelerate recovery, and reduce intensive supportive care and long-term hospitalization.

Yinhu Qingwen Decoction (Granula) consists of 11 common non-toxic traditional Chinese medicine such as Polygonum cuspidatum, Honeysuckle, Nepeta, Ligustrum lucidum. Previous vivo antiviral studies showed its activity for the inbition of CoVID-19. This clinical trial is planned to evaluate the mean clinical recovery time for patients with mild and common CoVID-19 infection as the primary outcome, and to evaluate the effect of the symptoms relief and virus clearance as well as the clinical safety.

Connect with a study center

  • Jingzhou Hospital of Traditional Chinese Medicine

    Jingzhou, Hubei 434000
    China

    Site Not Available

  • Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University

    Wuhan, Hubei 430200
    China

    Site Not Available

  • Xiangyang Hospital of Traditional Chinese Medicine

    Xiangyang, Hubei 441000
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.